Associated Papers
Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trial.
Slørdahl KS et al.
Acta Oncologica (stockholm, Sweden), 2026
Multi-center multi-omics integration predicts individualized prognosis in medullary thyroid carcinoma.
Zhou Y et al.
Nature Communications, 2026
Ancestry-dependent patterns of somatic mosaicism and clonal hematopoiesis mutations in over 125,000 individuals reveal distinct cancer associations.
Colin-Leitzinger C et al.
Human Genomics, 2025
Differential effects of RAS mutations on chemoradiotherapy and total neoadjuvant therapy in locally advanced rectal cancer.
Haraguchi E et al.
International Journal of Cancer, 2025
Functional Analysis of Rare RAS Variants of Unknown Significance.
Park S et al.
Cancer Research Communications, 2025
Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8-year study of 10 754 patients in Turkey.
Kavgaci G et al.
Molecular Oncology, 2025
U2AF1 mutations rescue deleterious exon skipping induced by KRAS mutations.
Walter DM et al.
Biorxiv : the Preprint Server for Biology, 2025
PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
Janku F et al.
Jco Precision Oncology, 2025
Clonal Hematopoiesis of Indeterminate Potential Is Associated With Incident Abdominal Aortic Aneurysm.
Tan Y et al.
Arteriosclerosis, Thrombosis, and Vascular Biology, 2025
Clinicopathologic characteristics, co-mutation landscape, and survival outcomes of KRAS-G12D mutant lung adenocarcinoma in comparison to KRAS-G12C and EGFR-mutated subtypes.
Abolfathi H et al.
Lung Cancer (amsterdam, Netherlands), 2025
Detection of actionable mutations in circulating tumor DNA for non-small cell lung cancer patients.
van der Leest P et al.
Communications Medicine, 2025
Genetic evolution and relapse-associated mutations in adult T-cell acute lymphoblastic leukemia patients treated in PETHEMA trials.
González-Gil C et al.
Hemasphere, 2025
Peripheral blood somatic mosaicism and clonal hematopoiesis across ancestry backgrounds.
Colin-Leitzinger C et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Comparative analysis of RNA expression in a single institution cohort of pediatric cancer patients.
Vasquez YA et al.
Npj Precision Oncology, 2025
Genomic Landscapes of Early-Onset Versus Average-Onset Colorectal Cancer Populations.
Storandt MH et al.
Cancers, 2025
Recurrent ETV3::NCOA2 fusions and MAPK pathway mutations in indeterminate dendritic cell histiocytosis.
Kemps PG et al.
Blood Advances, 2025
Genetic characterization of pediatric B-cell acute lymphoblastic leukemia in Argentina uncovers molecular heterogeneity and novel variants.
Sol Ruiz M et al.
Frontiers in Pharmacology, 2025
The theory of massively repeated evolution and full identifications of cancer-driving nucleotides (CDNs).
Zhang L et al.
Elife, 2024
Colchicine prevents accelerated atherosclerosis in TET2-mutant clonal haematopoiesis.
Zuriaga MA et al.
European Heart Journal, 2024
Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity.
Kwon JJ et al.
Biorxiv : the Preprint Server for Biology, 2024
KRAS mutations detection methodology: from RFLP to CRISPR/Cas based methods.
Morshedzadeh F et al.
Functional & Integrative Genomics, 2024
Exploring the Relationship Between KRAS, NRAS, and BRAF Mutations and Clinical Characteristics in Iranian Colorectal Cancer Patients.
Mosaferi Z et al.
Journal of Gastrointestinal Cancer, 2024
KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways.
Mondal K et al.
Cells, 2024
Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy.
Osumi H et al.
Nature Communications, 2024
CSF3R mutated myeloid neoplasms: Beyond chronic neutrophilic leukemia.
Mohamed A et al.
Human Pathology, 2024
Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study.
Hirsch P et al.
Blood Cancer Journal, 2024
Temporal dynamics of RAS mutations in circulating tumor DNA in metastatic colorectal cancer: clinical significance of mutation loss during treatment.
Iguchi K et al.
Journal of Cancer Research and Clinical Oncology, 2024
Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis.
Murakami S et al.
Cancer Medicine, 2024
Targeted next-generation sequencing of 491 lung cancers in clinical practice: Implications for future detection strategy and targeted therapy.
Liu XD et al.
Heliyon, 2024
Genetic modification of inflammation- and clonal hematopoiesis-associated cardiovascular risk.
Yu Z et al.
The Journal of Clinical Investigation, 2023
A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer.
Osumi H et al.
Translational Oncology, 2023
Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients.
Leest PV et al.
International Journal of Molecular Sciences, 2023
Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms.
Luque Paz D et al.
Hemasphere, 2023
Beyond Structural Bioinformatics for Genomics with Dynamics Characterization of an Expanded KRAS Mutational Landscape.
Ratnasinghe BD et al.
Biorxiv : the Preprint Server for Biology, 2023
Deep genomic characterization highlights complexities and prognostic markers of pediatric acute myeloid leukemia.
Cheng CK et al.
Communications Biology, 2023
Genomic characterization of DICER1-associated neoplasms uncovers molecular classes.
Kommoss FKF et al.
Nature Communications, 2023
KRAS, NRAS, BRAF, HER2 and MSI Status in a Large Consecutive Series of Colorectal Carcinomas.
Martianov AS et al.
International Journal of Molecular Sciences, 2023
KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer.
Shimozaki K et al.
Journal of Cancer Research and Clinical Oncology, 2023
Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma.
Ansari-Pour N et al.
Blood, 2023
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry.
Sargas C et al.
Cancers, 2023
BRCA1-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib.
Velazquez C et al.
Frontiers in Oncology, 2023
Case Report: Longitudinal monitoring of clonal evolution by circulating tumor DNA for resistance to anti-EGFR antibody in a case of metastatic colorectal cancer.
Sagawa T et al.
Frontiers in Oncology, 2023
Beyond structural bioinformatics for genomics with dynamics characterization of an expanded KRAS mutational landscape.
Ratnasinghe BD et al.
Computational and Structural Biotechnology Journal, 2023